Vlado Perkovic's Publications

• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

  Journal articles

  2025

  The Lancet Diabetes and Endocrinology

• The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol

  Journal articles

  2024

  JAMA network open

• Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes

  Journal articles

  2024

  Journal of the American College of Cardiology

• Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

  Journal articles

  2024

  Circulation

• Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply

  Journal articles

  2024

  The New England journal of medicine

• Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

  Journal articles

  2024

  European Heart Journal

• Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  European Heart Journal

• Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.

  Journal articles

  2024

  N Engl J Med

• Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

  Journal articles

  2024

  Journal of the American College of Cardiology

• Canagliflozin and iron metabolism in the CREDENCE trial

  Journal articles

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy

  Journal articles

  2024

  Kidney International Reports

• Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

  Journal articles

  2024

  Nature Medicine

• Kidney Disease as a Cardiovascular Disease Priority

  Journal articles

  2024

  Circulation

• Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  European Journal of Heart Failure

• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD A Meta-Analysis of CKD Progression Trials

  Journal articles

  2024

  Clinical Journal of the American Society of Nephrology

• Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

  Journal articles

  2024

  EUROPEAN HEART JOURNAL

• Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

  Journal articles

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

  Journal articles

  2024

  The Lancet Diabetes and Endocrinology

• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

  Journal articles

  2024

  Circulation

• Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes

  Journal articles

  2024

  New England Journal of Medicine

• The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy

  Journal articles

  2024

  Kidney International Reports

• Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

  Journal articles

  2024

  Circulation

• Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study

  Conference Papers

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION